Active Comparator: Study Design

The active comparator trial studied the efficacy and safety of Cayston compared to Tobramycin Nebulizer Solution (TNS)

Active Comparator Trial: Study design6

CAYSTON Active Comparator: study-design chart

Active Comparator Trial: Baseline demographics and clinical characteristics6

CAYSTON Active Comparator: Baseline demographics and clinical characteristics
*n=131, 131, and 262 for 3 columns.
Approved indication is for patients with FEV1 ≥25% or ≤75% predicted.
Enrollment included ≤40 patients with <84 days inhaled tobramycin use in the previous year. One patient was mistakenly stratified to ≥84 days, and 2 patients were mistakenly stratified to <84 days.
Learn About the Active Comparator Trial Efficacy Results
NEXT